Two Scientists Receive Robin Chemers Neustein Award

Early-career scientists Catherine Jensen Peña, PhD, and Zoi Karoulia, PhD, innovative investigators in the fields of neuroscience and cancer, respectively, were named recipients of the 2017 Robin Chemers Neustein Postdoctoral Fellowship Award.

The fellowship, intended to encourage and support female research scientists at the Icahn School of Medicine at Mount Sinai, was established in 2010 through a generous gift from Robin Chemers Neustein, JD, MBA, a former member of Mount Sinai’s Boards of Trustees. Recipients are senior postdoctoral scientists who have demonstrated high-impact accomplishments in the biomedical sciences and exhibit the potential for an independent scientific career. Each recipient is being awarded $25,000.

Dr. Peña works in the laboratory of Eric J. Nestler, MD, PhD, Dean for Academic and Scientific Affairs, Director of The Friedman Brain Institute, and Nash Family Professor of Neuroscience, researching the molecular mechanisms mediating earlylife stress and its impact on psychiatric disease vulnerability. Earlier this year, she was the lead investigator, and Dr. Nestler was the senior author, of a novel study published in Science.

Dr. Karoulia, a researcher in the laboratory of Poulikos Poulikakos, PhD, Assistant Professor, Oncological Sciences, is investigating the mechanisms that regulate oncogenic signaling in BRAF mutant tumors. The focus of her research is to characterize mechanisms of drug resistance in various clinical contexts, including resistant BRAFV600E melanomas, and colorectal and thyroid tumors, to develop more effective therapeutic approaches.

Catherine Jensen Peña, PhD

Zoi Karoulia, PhD

Q&A: What Women Need to Know about the New England Journal of Medicine Article on Breast Cancer Recurrence

Charles L. Shapiro MD, FASCO

The New England Journal of Medicine published an article November 9 about the long-term risks of breast cancer recurrence after stopping endocrine therapy at five years.

Here are some answers to patient questions from Charles L. Shapiro MD, FASCO, Professor of Medicine (Hematology and Oncology) at the Icahn School of Medicine at Mount Sinai and Director of Translational Breast Cancer Research and Director of Cancer Survivorship at The Tisch Cancer Institute.

Q: What is important about this study?
A: The idea that breast cancer can reoccur late is not new information. There were always a small minority of women who experience a recurrence 10, 15, 20 years and even more after the diagnosis and treatment of the original primary breast cancers.

Q: What is new in the study?

A: What is new in this study is the magnitude of late-appearing recurrences, and that breast cancer-specific mortality is higher than one would expect. However, there are several caveats. Although more than 60,000 women participated in more than 80 clinical trials cited by the study, these trials were designed many years ago and included all estrogen receptor-positive cancers. So much has changed in the last 25 years.

Q: Can you give an example?

A: One change is our recognition that there are at least two types of estrogen receptor-positive breast cancers, Luminal A (that have a lower chance of recurrence) and Luminal B (that have a higher chance of recurrence), with very different biological behaviors and different clinical outcomes. This study does not distinguish between these two types of estrogen receptor-positive breast cancers.  Also, there was no information in this study on patients who received adjuvant chemotherapy, and the studies didn’t use trastuzumab (Herceptin).  Adjuvant chemotherapy and trastuzumab are frequently used to treat Luminal B cancers.

 Q: What group of patients are affected by this study?

A:  Women with estrogen receptor-positive breast cancers, which represent about 75 percent of all breast cancers.

Q: Who is most at risk?

A:  Those most at risk of a recurrence are those treated decades earlier when treatment options and our knowledge of science were more limited.

Q: Should doctors immediately extend tamoxifen treatment to 10 years instead of five? If women have already gone off tamoxifen after five years, should they go back on?

A: No, not on the basis of this study. These trials were performed decades ago and do not reflect modern approaches to treatment in women with early stage estrogen receptor-positive breast cancers. For example, now we have tests based on genes expressed by the breast cancer that predict who is likely to recur five or more years after the original primary diagnosis. And more of these are coming.

 Q: Should breast cancer patients be worried?

A: Women now undergoing treatment do not need to be extra worried. These study results are from old clinical trials, and so they are just not as relevant to women diagnosed today. There are improvements in breast imaging that leads to diagnosis of breast cancer at an earlier, more curable stage. That coupled with advances in treatments and supportive care (such as improved drugs for nausea or growth factors that boost the white blood cell count and aid recovery from chemotherapy) has led to a steady decline in breast cancer mortality during the last 30-plus years. Also, our deepening knowledge of the biology of breast cancer has led and will lead to new therapies for estrogen receptor-positive breast cancers. The future is full of hope.

Q: What should I do if I have questions?

A:  Call your health care provider.

Will Ferrell and Mark Wahlberg Visit Kravis Children’s Hospital at Mount Sinai

Will Ferrell and Mark Wahlberg visit Sabrina Giangrande, a patient at Kravis Children’s Hospital at Mount Sinai

The stars of “Daddy’s Home 2,” Will Ferrell and Mark Wahlberg, brought smiles to the faces of pediatric patients during bedside visits at Kravis Children’s Hospital at Mount Sinai, on Thursday, November 9. The occasion was sponsored by Lollipop Theater Network, a nonprofit organization that works with motion picture studios to bring first-run movies to children in hospitals nationwide. In addition to the visit, several adolescent patients and their family members had the opportunity to watch the new movie at their bedsides. “It was wonderful, a real morale booster,” says Cheryl Strauss, Child Life Specialist with the Child Life and Creative Arts Therapy Department at Kravis Children’s Hospital. “Meeting the actors brightened the day for patients and their families.”

Patient Arianna Khelil and her mother, Maria Colletto-Khelil, meet with, from left, Max Schneider, Lollipop Theater Network, Mark Wahlberg, and Will Ferrell

 

Will Ferrell and Mark Wahlberg meet with, left to right, Charles Ennis, Senior Clinical Director, Women and Children’s Services, Mount Sinai Health System; Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System; and Frances Cartwright, PhD, Chief Nursing Officer and Senior Vice President , The Mount Sinai Hospital

 

A Robust Call to Action in Stemming Global Pollution

A boy collects drinking water from a rain puddle in Kabwe, Zambia, where the ground is full of lead after decades of mining. Inset: Study author Philip J. Landrigan, MD, MSc. Photo: Larry C. Price

For decades, families in Dong Mai, Vietnam, recycled used car batteries in their backyards and kitchens without any environmental controls. In Sovetskoe, Kyrgyzstan, homes, playgrounds, and schools were constructed with red sand that contained high levels of lead still present in the soil years after a Soviet-era metal processing factory was closed. In Madre de Dios, Peru, where livelihoods depend upon small-scale gold mining, dangerously high levels of mercury, a potent neurotoxin that is used to separate gold from other materials, have been found in the bodies of 78 percent of residents.

Indeed, rising levels of ambient air pollution, chemical pollution, and soil pollution are extracting a deadly toll on the lives of people around the world, in particular, the very young and very old, and those in low- and middle-income countries. The cost of pollution led to an estimated 9 million premature deaths in 2015—16 percent of all deaths worldwide. This number represents three times more deaths than from AIDS, tuberculosis, and malaria combined, and 15 times more than from all wars and other forms of violence.

These first-ever findings appear in the October 2017 issue of The Lancet in a study led by Philip J. Landrigan, MD, MSc, Dean for Global Health, Professor of Environmental Medicine, Public Health, and Pediatrics, Icahn School of Medicine at Mount Sinai; and Richard Fuller, Founder and President of the nongovernmental organization Pure Earth, and Secretariat of the Global Alliance on Health and Pollution. Dr. Landrigan and Mr. Fuller worked with Pamela Das, MD, Senior Executive Editor of The Lancet, in an exhaustive effort to document the data.

Study author Philip J. Landrigan, MD, MSc

“We want to turn this report into action,” said Dr. Landrigan, who spoke on Monday, October 23, at a special event on the Icahn School of Medicine at Mount Sinai campus that officially launched the study. The goal of the report, he said, was to raise global awareness of pollution and mobilize politicians to tackle it by providing them with comprehensive figures on its impact on human health and economics.

“Though the warnings are sobering, the optimistic message is that pollution can be addressed,” said Dr. Das.

The culmination of a two-year project that involved more than 14 international health agencies, the report is the first to document the global effects of environmental pollutants on human health and the worldwide economic costs of pollution-related disease and death. It also is the first study that brings together data on all forms of pollution, including air, water, soil, heavy metals, chemicals, and occupational pollutants. Pollution is defined as any material that people release into the environment that harms human health, and does not include naturally  occurring chemicals, cigarette smoke, drug abuse, or similar lifestyle factors.

At the event to launch The Lancet report, Dennis S. Charney, MD, reminded the audience of Mount Sinai’s decades-old role in promoting environmental health.

“We hope our findings will really elevate pollution within the political health agenda and inspire and encourage all levels of society to make pollution a priority,” said Dr. Das.

Speaking to the audience, Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System, said, “Mount Sinai will continue to investigate the role of the environment on health and disease and work with elected officials and others to impact changes that will improve the lives of our citizens and others around the world.”

Richard Fuller, co-author of the report

Pollution’s significant effect on the brains of developing fetuses and infants is particularly dire in the low-income and middle-income countries that have largely neglected the issue. Though they are diverse, middle-income countries—ranging from Kenya in the lower range to China in the upper range—comprise 5 billion of the world’s 7 billion people, and 73 percent of the world’s poor, according to the World Bank.

“A child with brain damage caused by pollution is never going to live the full potential of his life. It can’t be fixed but it can be prevented, and the next child can be protected,” Dr. Landrigan said.

Decades ago, Dr. Landrigan’s pioneering work led the U.S. government to remove lead from gasoline and paint, resulting in a more than 90 percent reduction in the incidence of childhood lead poisoning over the past 25 years.

Pamela Das, MD, the report’s editor

According to The Lancet report, the removal of lead from gasoline has returned an estimated $200 billion to the U.S. economy each year since 1980. To date, there has been an aggregate benefit of more than $6 trillion through the increased cognitive function and enhanced economic productivity of generations of children exposed since birth to only low amounts of lead. A decrease in IQ of one percentage point lowers lifetime earnings by as much as 2.4 percent, according to the study. Lower IQs also increase the cost to society by adding to the use of social welfare services and making incarceration more likely.

For every dollar invested in air pollution control since 1970, The Lancet reports that $30 has been returned to the U.S. economy, an aggregate benefit of $1.5 trillion on an investment of $65 billion.

A woman in Dong Mai, Vietnam, breaks down electrical transformers and other e-waste. Photo: Pure Earth www.pureearth.org

As a person’s exposure to pollution increases, his or her risk for noncommunicable diseases, including ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lung cancer, also increase. But the slow progression of these diseases over time is one reason why pollution has not garnered the same level of attention as say, the Zika virus. In Southeast Asia, where ambient air pollution is the worst in the world, Dr. Landrigan says pollution is expected to increase 50 percent by 2050 if aggressive interventions are not put in place.

Among the attendees at Mount Sinai’s kickoff event were former Mexican President Carlos Salinas de Gortari and former Environmental Protection Agency Administrator Regina McCarthy. Achim Steiner, Administrator of the United Nations Development Programme, an international agency that supports sustainable development, addressed the audience via video.

“Failure to take the report seriously is detrimental to our children, families, and communities, and also to our economies and the planet at large,” Mr. Steiner said. “It is not a luxury for rich countries but an imperative for all.”

 

Toddler Receives the Gift of Sound

With her new cochlear implant in place, Ruth relaxed with her mother, Nancy Komujuni.

Ruth Tatuleka, a 2-year-old from Uganda, was recently given the gift of hearing, thanks to a team of physicians and staff at the Mount Sinai Health System.

Ruth is from Kyabirwa, a village of 1,000 people, and has been deaf since birth. Her family knew that if she were ever to hear, the only solution was a cochlear implant—a small electronic device that stimulates the cochlear nerve, which carries auditory information to the brain. While commonplace in the United States, cochlear implant surgery is rare in the developing world. The family tried to raise funds to take Ruth to India—the closest country that could possibly perform the procedure—but they were unsuccessful. Meanwhile, time was running out, since a child’s first three years are crucial in learning spoken language.

Fortunately for Ruth, a slender lifeline connected her village to New York City: Ruth’s uncle, Charles Kalumuna, MD, volunteers his services at The Allan Stone Community Health Clinic in the village, where a new surgical facility is under construction with donations being raised by Michael L. Marin, MD, the Dr. Julius H. Jacobson II Chair in Vascular Surgery, Icahn School of Medicine at Mount Sinai, and Surgeon-in-Chief, Mount Sinai Health System.

Dr. Kalumuna reached out to Dr. Marin, who then contacted colleagues at Mount Sinai about Ruth’s case. By August, the little girl was at The Mount Sinai Hospital, undergoing surgery by Maura K. Cosetti, MD, Assistant Professor of Otolaryngology, Icahn School of Medicine at Mount Sinai, and Director of the Cochlear Implant Program at the Ear Institute of the New York Eye and Ear Infirmary at Mount Sinai. “Because hearing is closely tied to language development, our goal is to give children access to sound as early as possible,” Dr. Cosetti says. “We are thrilled to help Ruth and her family in this meaningful way.”

On Monday, September 11, the implant was activated, allowing Ruth to hear the sound of her parents’ voices for the first time—a milestone she met with a quizzical expression. The device was checked and programmed by Jillian Levine-Madoff, AuD, Cochlear Implant Audiologist at the Ear Institute. She established what the family had been hoping for: Ruth now has access to sound. The little girl then began speech therapy sessions, led by Jessica Van Manen, MA, Hearing Habilitation and Speech/Language Pathologist at the Ear Institute, which were a critical part of her recovery since she had previously communicated mainly through gestures.

Maura K. Cosetti, MD, left, Director of the Cochlear Implant Program at the New York Eye and Ear Infirmary at Mount Sinai, was assisted by resident Douglas Worrall, MD.

Ruth and her family are now back in their village, where they continue to work on her hearing and speech skills. “Ruth was granted a chance to reach her full potential, thanks to the amazing team at The Mount Sinai Hospital,” Dr. Kalumuna says. “She is a lot more active and happy now, and definitely enjoys hearing sounds!”

Dr. Marin says, “Seeing an outcome such as Ruth’s inspires me to push forward with changing the standard of how the Western world provides aid and surgical care to areas like Kyabirwa, where safe, accessible surgeries are so crucially needed.”

Urology Department Hosts International Symposium

From left: Ash Tewari, MBBS, MCh, with three of the speakers, Ashok Hemal, MD, Wake Forest Baptist Health; Peter Carroll, MD, MPH, University of California, San Francisco; and Eric Klein, MD, Cleveland Clinic.

More than 500 doctors, nurses, and other medical professionals recently attended the 2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic Oncology at The Mount Sinai Hospital. The three-day event in September was hosted by the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai and held in collaboration with the Society of Urologic Robotic Surgeons and the Endourological Society.

Participants included more than 80 of the world’s leading experts in prostate, kidney, and bladder cancers. There were more than 100 presentations on improving patient outcomes, the genomic complexity of prostate and kidney cancers, novel biomarkers, and updates on the latest treatment techniques, including focal therapy and fusion biopsy. The symposium also recognized the 75th Anniversary of the Department of Urology at the Icahn School of Medicine at Mount Sinai.

“We were gratified by the number of leaders in our field who chose to attend,” says Ash Tewari, MBBS, MCh, the Kyung Hyun Kim, MD, Chair in Urology, Mount Sinai Health System, and the Director of the symposium. “We believe this symposium underscored the value of collaborating with colleagues from different countries and specialties in order to improve care for patients. We have already started planning for next year’s symposium.”

Among this year’s highlights were live robotic prostate and kidney surgeries performed in 3-D and in real time by Dr. Tewari and symposium co-director Ketan Badani, MD, Vice Chair of Urology, Director of Robotic Surgery, and Director of the Comprehensive Kidney Cancer Program, Mount Sinai Health System. Mount Sinai’s Department of Urology runs one of the busiest robotic surgical programs in the United States for prostate, kidney, and bladder cancers.

“These live surgery and video presentations are invaluable teaching opportunities,” says Dr. Badani. “Wearing the special glasses and with the cinematic projection, attendees can experience the same high-resolution, three-dimensional view that we have while performing robotic surgery.”

Says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System: “The depth and breadth of programs—from live 3-D surgeries to point-counterpoint debates conducted by leaders in the field of urology—reflect impressive planning and organization on the part of Dr. Tewari and his team. Events such as these help advance the reputation of the Icahn School of Medicine at Mount Sinai.”

Leaders from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and the Lillian and Henry M. Stratton-Hans Popper Department of Pathology and Laboratory Medicine at the Mount Sinai Health System served as associate directors of the symposium. They included: Nina Bhardwaj, MD, PhD, Professor of Medicine (Hematology and Medical Oncology); Carlos Cordon-Cardo, MD, PhD, the Irene Heinz Given and John LaPorte Given Professor and Chair of the Department of Pathology at the Mount Sinai Health System; and William Oh, MD, Chief of the Division of Hematology and Medical Oncology, Professor of Medicine, and Urology, the Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics, and Associate Director for Clinical Research, The Tisch Cancer Institute.

“This comprehensive event made me realize how much is already known and how much more needs to be done to advance patient care,” says Ramon E. Parsons, MD, PhD, Director of The Tisch Cancer Institute, and the Ward-Coleman Chair in Cancer Research and Professor of Oncological Sciences.